Vaccine Info


RiVax® is Soligenix’s proprietary vaccine developed to protect against exposure to ricin toxin and is the most advanced vaccine product in the company’s portfolio.

With RiVax®, Soligenix is a world leader in ricin toxin vaccine research.

The immunogen in RiVax® induces a protective immune response in animal models of ricin exposure and functionally active antibodies in humans. The immunogen consists of a genetically inactivated subunit ricin A chain that is enzymatically inactive and lacks residual toxicity of the holotoxin.

April 8th, 2019